Chemotherapy-induced Thrombocytopenia clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
open to eligible people ages 18 years and up
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
at UCLA
Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Sorry, in progress, not accepting new patients
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
at UC Irvine
Our lead scientists for Chemotherapy-induced Thrombocytopenia research studies include Wanxing Chai-Ho.
Last updated: